Global Banking | Finance

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Business

By Uma Rajagopal

Posted on December 18, 2024

Nestle launches protein shots for US weight-loss drug users

By Richa Naidu

LONDON (Reuters) – Nestle is launching protein shots in the United States which it says help suppress appetite for people looking to shed pounds, the latest effort by the world’s biggest packaged food maker to tap the booming market for weight-loss products.

The manufacturer of Kit Kat chocolate bars and Nesquik shakes says its drink sparks a natural reaction in the body which is similar to, but far less powerful than, highly in-demand drugs for weight loss like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

The weekly weight-loss injections mimic an intestinal hormone called GLP-1 and curb people’s appetite, promoting a feeling of fullness.

The shake, called Boost Pre-Meal Hunger Support, is to be consumed up to 30 minutes before a meal and is aimed at people taking GLP-1 drugs or other weight-loss medications. The roll-out started last month.

“You get an increase in natural GLP-1 which helps in controlling the feeling of hunger. So this dose has a significant effect on satiety,” Stefan Palzer, chief technology officer at Nestle, told Reuters.

The shots, sold for $10.99 for a pack of four on Amazon.com and at some CVS stores, contain 10 grams of whey protein, 45 calories, 1 gram of sugar, and are fat-free. They are advertised as promoting a “NATURAL GLP-1 response to a meal.”

Palzer said they could also help people maintain their reduced weight.

Lora Heisler, chair in human nutrition and director of research at the Rowett Institute, said it was unclear if the shot could make a real long-term difference for people trying to lose weight.

“I believe that this protein shot can help release a bit more GLP-1, but you can also possibly have a similar sort of release with a glass of milk,” she said.

Earlier this year, Nestle started selling a new, $5 line of frozen pizzas and protein-enriched pastas in the United States designed for people taking weight-loss drugs.

Analysts estimate the obesity drug market could be worth as much as $150 billion per year globally within a decade.

When U.S. retail giant Walmart said last year it saw a slight pullback in food consumption when people took the medication, it sparked a selloff in shares of companies including Nestle.

MIX OF PEPTIDES

The shot, whose formula Nestle has patented, is not intended to replace weight loss drugs and is less powerful than them, Palzer said.

Nestle says the product is based on a mix of peptides which are digested quickly, giving the consumer an amino acid spike that then controls hunger.

Whey protein micro-gels help people digest more slowly, meaning they interact much longer with receptors in the intestine that are releasing the GLP-1 hormone.

In 2021, Nestle said 26 people with type-2 diabetes participated in a randomised study, consuming either a low-dose whey protein microgel or a placebo of water, followed by a meal designed to produce an adequate spike in glucose.

One week into the study, participants who had been taking the whey protein were given the placebo, and those who had been taking the placebo were given the whey protein.

Results showed that during the two hours after the meal, glucose levels were reduced by 22% in the whey-protein group compared with the placebo group. There was also a positive effect on the hormone GLP-1.

(Reporting by Richa Naidu. Additional reporting by Maggie Fick. Editing by Josephine Mason and Mark Potter)

Recommended for you

  • Swiss majority stake in Swisscom confirmed after review

  • Austrian coalition talks to continue into the new year, party leaders say

  • Insurer Direct Line rejects Aviva's $4.16 billion takeover bid